Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)

LONDON,  8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK). 

The two companies have entered into a definitive agreement under which Merck (known as MSD outside the United States and Canada), through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. 

Arix will provide a full financial update for its shareholders in due course.  

The announcement can be accessed on Harpoon Therapeutics’ website at: www.harpoontx.com and the full text of the announcement from the company is contained below.